I期小细胞肺癌SBRT与化疗序贯模式及结局
基于美国大型国家数据库,纳入2004-2020年接受SBRT和化疗的临床I期(cT1-2N0M0)小细胞肺癌患者631例,比较「SBRT先于化疗」与「SBRT同步或后于化疗」两种序贯模式。
要点
- 631例临床I期SCLC中,65.9%接受SBRT先于化疗,34.1%接受SBRT同步或后于化疗。
核心结论
- SBRT先于化疗与SBRT同步或后于化疗相比,患者生存结局无统计学显著差异,治疗序贯可灵活选择。
研究设计与样本
- 基于美国大型国家数据库的回顾性队列研究,纳入2004-2020年临床I期(cT1-2N0M0)接受SBRT和化疗的SCLC患者631例。
- 按治疗序贯分为「SBRT先于化疗」和「SBRT同步或后于化疗」两组,采用χ2检验、logistic回归、Cox比例风险模型及Kaplan-Meier法分析。
主要发现
- 631例中416例(65.9%)为SBRT先于化疗,215例(34.1%)为SBRT同步或后于化疗。
临床怎么用
- 对于临床I期SCLC接受SBRT和化疗的患者,SBRT与化疗的序贯顺序可根据临床情况灵活安排。
局限性
- 本研究为基于数据库的回顾性分析,可能存在选择偏倚和未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated practice patterns and survival outcomes associated with the sequencing of stereotactic body radiation therapy (SBRT) and chemotherapy in patients with clinical stage I small cell lung cancer (SCLC) in the United States. METHODS AND MATERIALS: Using a large national database, we identified patients with clinical stage I (cT1-2N0M0) SCLC treated with SBRT and chemotherapy between 2004 and 2020. To assess practice patterns in relation to survival outcomes, patients were categorized into 2 cohorts: "SBRT before chemotherapy" and "SBRT concurrent with or after chemotherapy." χ2 tests and logistic regression models were used to determine patient characteristics associated with treatment sequencing. Univariable and multivariable Cox proportional hazard models were used to assess the association between patient characteristics and survival outcomes. Overall survival was analyzed using the Kaplan-Meier method and compared via the log-rank test. Sensitivity analyses were performed using multivariable logistic regressions and Cox proportional hazards models for treatments with a 30-day overlap and clinical T stage stratification. RESULTS: Among 631 patients with clinical stage I SCLC who were treated with SBRT and chemotherapy, 416 (65.9%) were categorized in "SBRT before chemotherapy" and 215 (34.1%) in "SBRT concurrent with or after chemotherapy." Patients diagnosed after 2018 were less likely to receive SBRT concurrent with or after chemotherapy (odds ratio, 0.46; 95% CI, 0.32-0.66; P < .001). Patients diagnosed with clinical stage T2 were more likely to receive SBRT concurrent with or after chemotherapy (odds ratio, 1.76; 95% CI, 1.05-2.95; P = .03). No statistically significant difference in survival was observed between the 2 treatment sequencing cohorts ("SBRT before chemotherapy": median, 40.5 months vs "SBRT concurrent with or after chemotherapy": median, 35.6 months; log-rank P = .30). On multivariable analysis, SBRT sequencing was not associated with overall survival (hazard ratio = 1.11; P = .35; 95% CI, 0.89-1.37). CONCLUSIONS: Our findings suggest that there is no statistically significant difference in survival outcomes for patients who receive SBRT before chemotherapy compared with those who receive SBRT concurrent with or after chemotherapy. Therefore, flexibility in treatment sequencing may be appropriate in this population.
引用
- Ziaks TJ, Oh P, Hicks D, et al. Sequencing of Stereotactic Body Radiation Therapy and Chemotherapy in Stage I Small Cell Lung Cancer: Practice Patterns and Outcomes. Adv Radiat Oncol. 2026. PMID: 42935798. doi:10.1016/j.adro.2026.102175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。